Hylomorph

What Hylomorph does

Hylomorph AG is a Swiss clinical-stage MedTech company headquartered at Technopark Zurich, developing bioresorbable medical devices that prevent post-surgical implant complications. Its lead product, Vesta, is a bioresorbable, antibiotic-eluting envelope designed for Cardiac Implantable Electronic Devices (CIEDs) including pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy devices. Vesta mechanically stabilizes the CIED while delivering sustained, localized antibiotic elution to reduce infection risk — addressing a clinical problem where real-world infection rates reach 1 in 18 in high-risk patients, with untreated cases associated with >3x mortality, 9–18 day hospital stays, and $55–150k treatment costs.

The underlying platform combines FDA-approved biocompatible resorbable materials with tunable mechanical and chemical properties and a controlled-release technology for active compounds (antibiotics and other drugs). The materials fully resorb after implantation, eliminating the need for removal. The design is human-centered, with a stated 1-minute preparation time intended to fit cardiac surgical workflows. The company is pursuing FDA and CE mark approvals for its Hylomate product portfolio and has a pipeline extending into neuromodulation, orthopedics, reconstructive surgery, surgical meshes, and ventricular assist devices.

Hylomorph is pre-commercial: Vesta is described as a "medical device under development." The business model centers on direct hospital sales of single-use hardware devices to electrophysiologists and cardiologists, with a future potential licensing stream for the proprietary biomaterial and drug-elution platform across other implant categories. The company has raised approximately CHF 17–18 million equivalent across multiple rounds through 2023, including an oversubscribed Series B2 led by EFI Lake Geneva Ventures and CHF 2.4 million of non-dilutive Innosuisse funding, and employs 11–50 people under a co-founder-led management team (CEO Simone Bottan, CSO Aldo Ferrari, COO Francesco Robotti).

Name

Hylomorph

Legal name

Hylomorph AG

Website

https://hylomorph-medical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Hylomorph AG is a Swiss clinical-stage MedTech company developing Vesta, a bioresorbable antibiotic-eluting envelope that prevents infections in cardiac implantable electronic devices (CIEDs) for electrophysiologists and cardiologists.

Ownership category

akta.pro rank

Product category

Cardiac Implantable Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)

akta.pro secondary industries

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

Keywords

• Bioresorbable medical implants
• Antibiotic eluting envelopes
• Cardiac implantable devices
• Medical device manufacturing
• Implant infection prevention

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Sale of medical devices including the Vesta antibiotic eluting envelope for Cardiac Implantable Electronic Devices (CIEDs). Revenue generated from product sales to hospitals and cardiac centers upon regulatory approval and market launch.
2. Technology Licensing: Potential licensing of proprietary biomaterial technology and antibiotic elution platform for various implant applications in neuromodulation, orthopedics, and other medical device categories.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Hylomorph develops and manufactures bioresorbable, antibiotic-eluting medical device envelopes that prevent post-surgical infections in implantable medical devices. Its lead product, Vesta, is a bioresorbable envelope for Cardiac Implantable Electronic Devices (CIEDs) including pacemakers, ICDs, and CRTs, providing mechanical stabilization and sustained localized antibiotic elution that fully resorbs in the body. The company also advances the Hylomate product portfolio targeting infection prevention across neuromodulation, orthopedics, reconstructive surgery, surgical meshes, and ventricular assist devices.

Product overview

Hylomorph develops innovative medical devices and drug-device combinations that prevent implant complications and ensure patient well-being post-surgery. The company offers the Vesta product (bioresorbable, antibiotic eluting CIED envelope) as its primary commercial offering, along with the Hylomate product portfolio. The pipeline includes future expansion into neuromodulation (Deep Brain & Spinal Cord Stimulation, Pain Management), orthopedics (Bone Fixation Plates), reconstructive surgery (Breast Reconstruction), surgical meshes (Hernia, Pelvic Prolapse), and ventricular assist devices (Bridge to transplant). The company operates from Technopark Zurich and targets Electrophysiologists and Cardiologists in the cardiac space, with plans to expand into neuromodulation and other medical specialties.

Differentiator

Problem solved

Functional benefit

Brands

• Vesta: Bioresorbable, antibiotic eluting envelope for Cardiac Implantable Electronic Devices (CIEDs) including Pacemakers, Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapies (CRTs). Designed for Electrophysiologists and Cardiologists.

Products and services

• Vesta Vesta is a bioresorbable, antibiotic-eluting envelope designed for Electrophysiologists and Cardiologists who implant Cardiac Implantable Electronic Devices (CIEDs), including Pacemakers, Implantable Cardioverter-Defibrillators (ICDs), and Cardiac Resynchronization Therapies (CRTs). The envelope holds and stabilizes the CIED while providing sustained, localized elution of antibiotics to reduce post-surgical infection complications, then fully resorbs in the body. All Vesta materials are FDA-approved for implantable medical devices.
• Hylomate product portfolio Hylomate is Hylomorph's product portfolio designed to reduce post-surgical complications in medical implants, targeting the cardiac and neuromodulation markets. The portfolio encompasses the Vesta CIED envelope as the lead product, with pipeline applications planned in neuromodulation (Deep Brain & Spinal Cord Stimulation, Pain Management), orthopedics (Bone Fixation Plates), reconstructive surgery (Breast Reconstruction), surgical meshes (Hernia, Pelvic Prolapse), and ventricular assist devices (Bridge to transplant).

Quantifiable outcome

• 1 in 18 real-world infection rate in high-risk CIED patients
• +4 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Penn Medicine - Dr Robert SchallercoreStrategic or Co-development PartnerDr Robert Schaller from Penn Medicine, Philadelphia serves as a Clinical Advisor to Hylomorph, providing clinical guidance and expertise for product development and regulatory strategy.
• Sant'Orsola Hospital Italy - Dr Mauro BifficoreStrategic or Co-development PartnerDr Mauro Biffi from Sant'Orsola Hospital Italy serves as a Clinical Advisor to Hylomorph, contributing cardiac electrophysiology expertise for product validation and clinical trial design.
• German Heart Center Charité - Dr Christoph StarckcoreStrategic or Co-development PartnerDr Christoph Starck from German Heart Center Charité serves as a Clinical Advisor to Hylomorph, providing expertise in cardiac device implantation and infection prevention.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Medtronic: Medtronic manufactures the TYRX antibiotic-eluting envelope, the leading commercialized CIED infection-prevention product. Direct competitor to Hylomorph's Vesta in the same clinical indication, with established hospital sales infrastructure and reimbursement.
• Aziyo Biologics: Aziyo develops biologic products for cardiac surgery, regenerative medicine, and implantable device applications. Comparable as a company creating biologic and bioresorbable solutions to address surgical and implant-related complications.

Emerging players

• CorMatrix: CorMatrix develops ECM-based biomaterials for cardiac and vascular tissue repair. Comparable as a smaller peer building bioresorbable implant solutions for cardiac surgery applications.
• PolyNovo: PolyNovo develops bioresorbable polymer platforms for wound care and surgical applications. Comparable as a peer with proprietary bioresorbable material technology applied to medical implants and surgical use cases.
• Tepha Inc. Tepha develops proprietary resorbable polymer technologies for medical devices and tissue engineering. Comparable as an emerging player with bioresorbable material IP serving implantable applications.

Broad incumbents

• Boston Scientific: Boston Scientific is a major CIED manufacturer (pacemakers, ICDs, CRTs) and would be a natural strategic acquirer or licensing partner for Hylomorph's Vesta envelope. Highly relevant as a potential commercial channel partner.
• Abbott: Abbott is a leading CIED manufacturer and offers cardiac devices across rhythm management, heart failure, and structural heart. Represents a large incumbent potential strategic partner or competitor if it expands its CIED accessory portfolio.
• Biotronik: Biotronik manufactures pacemakers, ICDs, and CRT devices. Comparable as a CIED incumbent whose installed base represents the customer universe for Hylomorph's Vesta envelope.

Regional players

• AtriCure: AtriCure develops cardiac surgery ablation and left atrial appendage management devices. Comparable as a peer operating in the cardiac surgery device space, though focused on different procedural indications.

Others

• LeMaitre Vascular: LeMaitre Vascular develops implantable devices for vascular and cardiac surgery. Comparable as a smaller medical device company serving surgical implant use cases relevant to Hylomorph's pipeline expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hylomorph-ag
• Xx.com/HYLOMORPH

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds10 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hylomorph